Simcere Pharmaceutical Group (HKSE:02096) Change In Receivables : HK$0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Simcere Pharmaceutical Group Change In Receivables?

Simcere Pharmaceutical Group's change in receivables for the quarter that ended in Dec. 2023 was HK$0 Mil. It means Simcere Pharmaceutical Group's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

Simcere Pharmaceutical Group's change in receivables for the fiscal year that ended in Dec. 2023 was HK$-337 Mil. It means Simcere Pharmaceutical Group's Accounts Receivable increased by HK$337 Mil from Dec. 2022 to Dec. 2023 .

Simcere Pharmaceutical Group's Accounts Receivable for the quarter that ended in Dec. 2023 was HK$2,183 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Simcere Pharmaceutical Group's Days Sales Outstanding for the six months ended in Dec. 2023 was 112.84.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Simcere Pharmaceutical Group's liquidation value for the six months ended in Dec. 2023 was HK$210 Mil.

Simcere Pharmaceutical Group Change In Receivables Historical Data

The historical data trend for Simcere Pharmaceutical Group's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group Change In Receivables Chart

Simcere Pharmaceutical Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-429.96

-642.68

-667.58

84.03

-336.72

Simcere Pharmaceutical Group Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial							-	-	-	-	-

Simcere Pharmaceutical Group Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.

Simcere Pharmaceutical Group (HKSE:02096) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Simcere Pharmaceutical Group's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2183.451	/	3531.239	*	91
=	112.84

2. In Ben Graham's calculation of liquidation value, Simcere Pharmaceutical Group's accounts receivable are only considered to be worth 75% of book value:

Simcere Pharmaceutical Group's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2207.573	-	3971.436	+	0.75 * 2183.451	+	0.5 * 672.195
=	210

Simcere Pharmaceutical Group Change In Receivables Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Simcere Pharmaceutical Group (HKSE:02096) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (HKSE:02096) » Definitions » Change In Receivables

Traded in Other Exchanges

S2P:Germany

Address

No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042

Website

https://www.simcere.com

Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Executives

Wang Xi	2305 Beneficiary of a trust
Ren Jinsheng	2202 Interest of your spouse
Right Wealth Holdings Limited	2501 Other
Wang Xi	2501 Other
Simcere Investments Group Limited	2501 Other
Excel Investments Group Limited	2501 Other
Simcere Pharmaceutical Holding Limited	2501 Other
Simcere Holding Limited	2501 Other
Artking Global Limited	2501 Other
Ren Zhen	2501 Other
Ren Yong	2501 Other
Ren Weidong	2501 Other
Peng Suqin	2501 Other
P&h Holdings Group Ltd.	2501 Other
Li Shimeng	2501 Other

Simcere Pharmaceutical Group (HKSE:02096) Headlines

No Headlines